Bacinschi XE, et al. - Among breast cancer patients (pts) referred to the Institute of Oncology and Oncofort Clinic, Bucharest, for neoadjuvant, sequential, taxane-containing chemotherapy, researchers performed this retrospective study to compare two regimens: weekly paclitaxel (Ptx) vs q3w docetaxel (Dtx), in terms of efficacy and safety. The eligible patients were 47 in total, with median age 56 years, mainly stage IIIA–B (53.2%, 25 pts) and ductal invasive (70.2%, 33 pts). A total of 24 pts (51%) were treated with q3w Dtx and 23 (48.9%) received weekly Ptx. The histological response rates were reported to be 62.5% (15 pts) and 73.7% (17 pts), respectively, and average dose-intensity was 87.7% and 96.7%. The grade III–IV toxicity rate was estimated to be 12.5% and 13%, respectively. A correlation of pathologic response with immunophenotype, PgR expression, tumor size and backbone chemotherapy, was identified. Overall, taxane’s weekly administration afforded an improved efficacy, seemingly because of better tolerance and a lower rate of dose-impairing toxicities.